AMRX

Amneal Pharmaceuticals Stock Analysis

AI Rating

Great
  • Quality9/10
  • Growth↑ 8/10
  • Momentum↑ 8/10
Amneal Pharmaceuticals sales and earnings growth
AMRX Growth
Good
  • Revenue Y/Y↑ 9.50%
  • EPS Y/Y↑ 102.33%
  • FCF Y/Y↓ -4.63%
Amneal Pharmaceuticals gross and profit margin trends
AMRX Profitability
Neutral
  • Gross margin ↑ 36.80%
  • EPS margin↓ 0.20%
  • ROIC↓ 7.20%
Amneal Pharmaceuticals net debt vs free cash flow
AMRX Risk
Great
  • Debt / Equity↓ -24.4
  • Debt / FCF↑ 9.8
  • Interest coverage↓ 1.1

Amneal Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗